OBARCIF (cefixime) is a broad-spectrum, third-generation cephalosporin antibiotic. Its bactericidal action results from inhibition of cell wall synthesis.

Each 5 ml of OBARCIF suspension contains: Cefixime trihydrate equivalent to cefixime 100 mg.

OBARCIF is indicated in the treatment of adults and pediatric patients six months of age or older with:

Uncomplicated Urinary Tract Infections

caused by susceptible isolates of Escherichia coli and Proteus mirabilis.

Otitis Media

caused by susceptible isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.

Note: For patients with otitis media caused by Streptococcus pneumoniae, overall response was approximately 10% lower for cefixime than for the comparator.

Pharyngitis and Tonsillitis

caused by susceptible isolates of Streptococcus pyogenes. (Note: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes infections. Cefixime is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, data establishing the efficacy of Cefixime in the subsequent prevention of rheumatic fever is not available).

Acute Exacerbations of Chronic Bronchitis

caused by susceptible isolates of Streptococcus pneumoniae and Haemophilus influenzae.

Uncomplicated Gonorrhea (cervical/urethral)

caused by susceptible isolates of Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producing isolates).

Pregnancy& breast-feeding

Pregnancy: OBARCIF is safe to use during pregnancy. (Pregnancy category: B).

Breast-feeding: It is not known whether cefixime is excreted in human milk. Consideration should be given to discontinuing nursing temporarily during treatment with this drug.

The recommended dose is 8 mg/kg/day of the suspension. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours.